Glasner-Edwards Suzette, Marinelli-Casey Patricia, Hillhouse Maureen, Ang Alfonso, Mooney Larissa J, Rawson Richard
UCLA Integrated Substance Abuse Programs, UCLA, Los Angeles, California, USA.
J Nerv Ment Dis. 2009 Apr;197(4):225-31. doi: 10.1097/NMD.0b013e31819db6fe.
Although depression is highly comorbid with substance use disorders, little is known about the clinical course and outcomes of methamphetamine (MA) users with depressive symptoms and syndromes. In this study of MA-dependent individuals entering psychosocial treatment, we predicted that (1) depressive symptoms would decline during treatment, an effect that would vary as a function of MA use and (2) depression diagnoses post-treatment would be associated with poorer outcomes. Participants (N = 526) were assessed for depression, substance use, and psychosocial outcomes at baseline, treatment discharge, and 3-year follow-up. Depressive symptoms declined significantly during treatment, an effect that was greatest among those who abstained from MA. Major depression at follow-up was associated with poorer MA use outcomes and impairment across multiple domains of functioning. The findings highlight the relationship of depressive symptoms and diagnoses to treatment outcomes, and suggest a need for further studies of depression in populations using MA.
尽管抑郁症与物质使用障碍高度共病,但对于有抑郁症状和综合征的甲基苯丙胺(MA)使用者的临床病程和结局知之甚少。在这项针对接受心理社会治疗的MA依赖个体的研究中,我们预测:(1)抑郁症状在治疗期间会减轻,这种效果会因MA使用情况而异;(2)治疗后的抑郁症诊断与较差的结局相关。在基线、治疗出院时和3年随访时,对参与者(N = 526)进行了抑郁、物质使用和心理社会结局评估。抑郁症状在治疗期间显著减轻,在戒除MA的人群中这种效果最为明显。随访时的重度抑郁症与较差的MA使用结局以及多个功能领域的损害相关。这些发现突出了抑郁症状和诊断与治疗结局的关系,并表明需要对使用MA人群中的抑郁症进行进一步研究。